Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis
We investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed se...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/8/598 |
| _version_ | 1827709364505411584 |
|---|---|
| author | Matteo Bauckneht Domenico Albano Salvatore Annunziata Giulia Santo Priscilla Guglielmo Viviana Frantellizzi Alessia Branca Cristina Ferrari Antonio Vento Alessia Mirabile Anna Giulia Nappi Laura Evangelista Pierpaolo Alongi Riccardo Laudicella |
| author_facet | Matteo Bauckneht Domenico Albano Salvatore Annunziata Giulia Santo Priscilla Guglielmo Viviana Frantellizzi Alessia Branca Cristina Ferrari Antonio Vento Alessia Mirabile Anna Giulia Nappi Laura Evangelista Pierpaolo Alongi Riccardo Laudicella |
| author_sort | Matteo Bauckneht |
| collection | DOAJ |
| description | We investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed selecting studies in presence of: sample size ≥10 patients; index test (i.e., 68Ga-DOTATOC or 68Ga-DOTANOC or 68Ga-DOTATATE PET/CT); and outcomes (i.e., detection rate (DR), true positive, true negative, false positive, and false-negative). The methodological quality was evaluated with QUADAS-2. Pooled DR and pooled sensitivity and specificity for the identification of the primary tumor were assessed by a patient-based and a lesion-based analysis. Thirty-eight studies were selected for the qualitative analysis, while 18 papers were included in the meta-analysis. The number of pNET patients ranged from 10 to 142, for a total of 1143 subjects. At patient-based analysis, the pooled sensitivity and specificity for the assessment of primary pNET were 79.6% (95% confidence interval (95%CI): 71–87%) and 95% (95%CI: 75–100%) with a heterogeneity of 59.6% and 51.5%, respectively. Pooled DR for the primary lesion was 81% (95%CI: 65–90%) and 92% (95%CI: 80–97%), respectively, at patient-based and lesion-based analysis. In conclusion, SSR-PET/CT has high DR and diagnostic performances for primary lesion and initial staging of pNETs. |
| first_indexed | 2024-03-10T17:21:01Z |
| format | Article |
| id | doaj.art-0cd6ad0d61f24f44912cdbb95353e0a8 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T17:21:01Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-0cd6ad0d61f24f44912cdbb95353e0a82023-11-20T10:20:25ZengMDPI AGDiagnostics2075-44182020-08-0110859810.3390/diagnostics10080598Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-AnalysisMatteo Bauckneht0Domenico Albano1Salvatore Annunziata2Giulia Santo3Priscilla Guglielmo4Viviana Frantellizzi5Alessia Branca6Cristina Ferrari7Antonio Vento8Alessia Mirabile9Anna Giulia Nappi10Laura Evangelista11Pierpaolo Alongi12Riccardo Laudicella13Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, ItalyDepartment of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, ItalyNuclear Medicine Unit, IRCSS Regina Elena National Cancer Institute, 00168 Rome, ItalyNuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70121 Bari, ItalyNuclear Medicine Unit, AO Brotzu, 09134 Cagliari, ItalyDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, ItalyNuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70121 Bari, ItalyNuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70121 Bari, ItalyDepartment of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, ItalyDepartment of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, ItalyNuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70121 Bari, ItalyNuclear Medicine Unit, Department of Medicine-DIMED, University of Padova, 35128 Padova, ItalyUnit of Nuclear Medicine, Fondazione Istituto G.Giglio, 90015 Cefalù, ItalyDepartment of Biomedical and Dental Sciences and of Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, ItalyWe investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed selecting studies in presence of: sample size ≥10 patients; index test (i.e., 68Ga-DOTATOC or 68Ga-DOTANOC or 68Ga-DOTATATE PET/CT); and outcomes (i.e., detection rate (DR), true positive, true negative, false positive, and false-negative). The methodological quality was evaluated with QUADAS-2. Pooled DR and pooled sensitivity and specificity for the identification of the primary tumor were assessed by a patient-based and a lesion-based analysis. Thirty-eight studies were selected for the qualitative analysis, while 18 papers were included in the meta-analysis. The number of pNET patients ranged from 10 to 142, for a total of 1143 subjects. At patient-based analysis, the pooled sensitivity and specificity for the assessment of primary pNET were 79.6% (95% confidence interval (95%CI): 71–87%) and 95% (95%CI: 75–100%) with a heterogeneity of 59.6% and 51.5%, respectively. Pooled DR for the primary lesion was 81% (95%CI: 65–90%) and 92% (95%CI: 80–97%), respectively, at patient-based and lesion-based analysis. In conclusion, SSR-PET/CT has high DR and diagnostic performances for primary lesion and initial staging of pNETs.https://www.mdpi.com/2075-4418/10/8/598pancreasneuroendocrine tumorspositron emission tomographysomatostatin receptor analogs |
| spellingShingle | Matteo Bauckneht Domenico Albano Salvatore Annunziata Giulia Santo Priscilla Guglielmo Viviana Frantellizzi Alessia Branca Cristina Ferrari Antonio Vento Alessia Mirabile Anna Giulia Nappi Laura Evangelista Pierpaolo Alongi Riccardo Laudicella Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis Diagnostics pancreas neuroendocrine tumors positron emission tomography somatostatin receptor analogs |
| title | Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis |
| title_full | Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis |
| title_fullStr | Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis |
| title_short | Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis |
| title_sort | somatostatin receptor pet ct imaging for the detection and staging of pancreatic net a systematic review and meta analysis |
| topic | pancreas neuroendocrine tumors positron emission tomography somatostatin receptor analogs |
| url | https://www.mdpi.com/2075-4418/10/8/598 |
| work_keys_str_mv | AT matteobauckneht somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT domenicoalbano somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT salvatoreannunziata somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT giuliasanto somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT priscillaguglielmo somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT vivianafrantellizzi somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT alessiabranca somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT cristinaferrari somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT antoniovento somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT alessiamirabile somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT annagiulianappi somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT lauraevangelista somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT pierpaoloalongi somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis AT riccardolaudicella somatostatinreceptorpetctimagingforthedetectionandstagingofpancreaticnetasystematicreviewandmetaanalysis |